Ernexa Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ERNA research report →
Companywww.ernexatx.com
Ernexa Therapeutics Inc. , a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
- CEO
- Sanjeev Luther
- IPO
- 1991
- Employees
- 6
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $3.58M
- P/E
- -0.79
- P/S
- 0.00
- P/B
- 1.32
- EV/EBITDA
- 0.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -263.68%
- ROIC
- -138.67%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-14,084,000 · 68.38%
- EPS
- $-56.00 · -42.68%
- Op Income
- $-9,319,000
- FCF YoY
- 56.47%
Performance & Tape
- 52W High
- $93.75
- 52W Low
- $3.18
- 50D MA
- $6.34
- 200D MA
- $23.98
- Beta
- 1.89
- Avg Volume
- 1.67M
Get TickerSpark's AI analysis on ERNA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 10, 26 | Cherington Charles | buy | 4,000,000 |
| Feb 10, 26 | Cherington Charles | buy | 4,000,000 |
| Jun 21, 25 | Gurrola Sandra M | other | 30 |
| Jun 21, 25 | Gurrola Sandra M | other | 30 |
| Jun 9, 25 | Cherington Charles | buy | 21,241,163 |
| Sep 24, 24 | Cherington Charles | buy | 1,562,988 |
| Sep 24, 24 | Cherington Charles | buy | 5,420,823 |
| Sep 24, 24 | Cherington Charles | buy | 1,237,762 |
| Sep 24, 24 | Cherington Charles | buy | 4,768,783 |
| Sep 24, 24 | Cherington Charles | buy | 261,756 |
Our ERNA Coverage
We haven't published any research on ERNA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ERNA Report →